Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
Immunotherapy
Newcastle disease virus
Oncolytic vector
Reverse genetics
Virus rescue
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
15
12
2020
Statut:
ppublish
Résumé
Newcastle disease virus (NDV) is an avian paramyxovirus that has been extensively studied as an oncolytic agent, in addition to being an economically important pathogen in the poultry industry. The establishment of a reverse genetics system for this virus has enabled the development of genetically modified recombinant NDV viruses with improved oncolytic and immunotherapeutic properties. In this chapter, we describe the materials and methods involved in the in vitro cloning and rescue of NDV expressing murine 4-1BBL as well as the in vivo evaluation of NDV expressing 4-1BBL in a B16-F10 murine melanoma model.
Identifiants
pubmed: 31486036
doi: 10.1007/978-1-4939-9794-7_9
pmc: PMC7370866
mid: NIHMS1607708
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-154Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Arch Gesamte Virusforsch. 1957;7(4):403-11
pubmed: 13521956
Virology. 2005 Jan 20;331(2):396-406
pubmed: 15629782
J Natl Cancer Inst. 1967 Dec;39(6):1089-97
pubmed: 6079863
mSphere. 2017 Mar 29;2(2):
pubmed: 28405630
J Virol. 2005 Nov;79(21):13275-84
pubmed: 16227250
Curr Opin Mol Ther. 2003 Dec;5(6):618-24
pubmed: 14755888
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.1
pubmed: 18432774
Med Oncol Tumor Pharmacother. 1992;9(4):169-71
pubmed: 1342060
Cancer Detect Prev. 1993;17(6):619-27
pubmed: 8275514
World J Urol. 1995;13(3):171-3
pubmed: 7550390
Annu Rev Immunol. 2005;23:23-68
pubmed: 15771565
Arch Virol. 2017 Jul;162(7):1845-1854
pubmed: 28316014
Head Neck. 2011 Oct;33(10):1394-9
pubmed: 21928411
Nat Commun. 2017 Feb 13;8:14340
pubmed: 28194010
J Clin Oncol. 2002 May 1;20(9):2251-66
pubmed: 11980996
Future Microbiol. 2012 Mar;7(3):347-67
pubmed: 22393889
Cancer Res. 2007 Sep 1;67(17):8285-92
pubmed: 17804743
Mol Ther. 2006 Jan;13(1):221-8
pubmed: 16257582
J Gen Virol. 2003 Apr;84(Pt 4):781-788
pubmed: 12655078
Proc Soc Exp Biol Med. 1955 Oct;90(1):82-6
pubmed: 13273360
Mol Ther. 2008 Nov;16(11):1883-90
pubmed: 18714310
Cancer. 1965 Jul;18:863-8
pubmed: 14308233
J Gen Virol. 2015 Jan;96(Pt 1):40-45
pubmed: 25274858
J Mol Med (Berl). 2010 Jun;88(6):589-96
pubmed: 20393691
Biomedicines. 2016 Jul 20;4(3):
pubmed: 28536382
J Virol. 1999 Jun;73(6):5001-9
pubmed: 10233962
J Surg Res. 1992 May;52(5):448-53
pubmed: 1619912
Mol Med. 1998 Dec;4(12):783-94
pubmed: 9990864
Mol Ther. 2009 Apr;17(4):697-706
pubmed: 19209145
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
J Gen Virol. 1998 Oct;79 ( Pt 10):2419-24
pubmed: 9780047
Cancer. 1977 Aug;40(2):680-6
pubmed: 196740
J Bacteriol. 1966 Sep;92(3):792
pubmed: 4288498
Prog Vet Microbiol Immunol. 1989;5:16-64
pubmed: 2696520
Cancer Biother. 1994 Fall;9(3):225-35
pubmed: 7820184
J Virol. 2001 Dec;75(23):11868-73
pubmed: 11689668
J Clin Virol. 2000 Feb;16(1):1-15
pubmed: 10680736
Oncotarget. 2018 Jun 19;9(47):28702-28716
pubmed: 29983890
Viruses. 2016 Jul 04;8(7):
pubmed: 27384578
Microb Pathog. 2004 Jan;36(1):1-10
pubmed: 14643634
J Neurooncol. 2004 Mar-Apr;67(1-2):83-93
pubmed: 15072452